.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
UBS
Julphar
McKesson
Medtronic
QuintilesIMS
Federal Trade Commission
Merck
Express Scripts
Chinese Patent Office

Generated: December 14, 2017

DrugPatentWatch Database Preview

PRELUDIN Drug Profile

« Back to Dashboard

When do Preludin patents expire, and what generic alternatives are available?

Preludin is a drug marketed by Boehringer Ingelheim and is included in two NDAs.

The generic ingredient in PRELUDIN is phenmetrazine hydrochloride. Additional details are available on the phenmetrazine hydrochloride profile page.
Drug patent expirations by year for PRELUDIN

Medical Subject Heading (MeSH) Categories for PRELUDIN

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Boehringer IngelheimPRELUDINphenmetrazine hydrochlorideTABLET, EXTENDED RELEASE;ORAL011752-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Boehringer IngelheimPRELUDINphenmetrazine hydrochlorideTABLET, EXTENDED RELEASE;ORAL011752-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Boehringer IngelheimPRELUDINphenmetrazine hydrochlorideTABLET;ORAL010460-005Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Deloitte
Fish and Richardson
Boehringer Ingelheim
Julphar
Chubb
QuintilesIMS
Citi
Mallinckrodt
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot